Blood Disorders Overtake Cancer On EMA’s PRIME Scheme

uniQure has become the third company to get accepted on the European Medicines Agency’s PRIME (priority medicines) scheme for a gene therapy for hemophilia, making hematology-hemostaseology the most common therapeutic areas for products on the scheme.

RedBloodCellsOnWhite_1200x675
Another drug for a blood disorder has made it on the EMA's PRIME scheme

Blood disorders have overtaken cancer as most common therapeutic area being targeted by drugs on the European Medicines Agency's PRIME scheme for the priority review of medicines for unmet medical need.

A gene therapy that uniQure is developing for severe hemophilia B has become the latest product to make it on...

More from Europe

More from Geography